Literature DB >> 19622268

Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care.

Björn Wettermark1, Ake Pehrsson, Maria Juhasz-Haverinen, Aniko Veg, Maria Edlert, Gunilla Törnwall-Bergendahl, Henrik Almkvist, Brian Godman, Fredrik Granath, Ulf Bergman.   

Abstract

BACKGROUND: Financial incentives have been suggested to be effective in increasing the quality and efficiency of drug prescribing. Concern has been raised in relation to potential negative consequences on the quality of care. AIMS: To describe and analyse the impact of an incentives model linking payment with adherence to drug and therapeutics committee (DTC) guidelines and self-reflection of prescribing pattern in a 'prescribing quality report'.
METHODS: The study was performed in the county of Stockholm, Sweden, with 139 (out of 154) primary healthcare centres (PHCs) participating in the project and 15 PHCs not participating. The study consisted of two parts: a quantitative observational study of prescribing patterns and a qualitative analysis of the submitted prescribing quality reports. All prescriptions issued from PHCs and dispensed at pharmacies during October to December 2005 and October to December 2006 were analysed, using adherence to the regional DTC guidelines as the main outcome measure. Adherence was assessed using the drug utilisation 90% methodology, i.e. focusing on drugs constituting 90% of the prescribed volume and the proportion of drugs included in the guidelines. The qualitative analysis focused on reports on the quality of drug prescribing submitted by each PHC in early 2007.
RESULTS: The 139 PHCs participating in the programme accounted for 85% of all prescriptions issued in primary care during October to December 2006. Mean adherence to guidelines increased among participating practices by 3.3 percentage units (95% confidence interval (CI) 2.9-3.7%) to 83% (82.6-83.7%) during the year. The adherence among practices not participating increased by 3.1 percentage units (95% CI 1.7-4.4%) to 78.8% (95% CI 76.7-80.9%). The higher adherence achieved during the year corresponded to savings estimated at five times greater than the cost of running the programme including the financial incentives. In addition, many areas for improving prescribing were identified, such as limiting the prescribing of drugs with uncertain safety profiles and documentation as well as reporting adverse drug reactions.
CONCLUSION: Although no causal effect can be attributed without a control group, we have shown the feasibility of a model linking payment to DTC adherence. This approach with its own quality assessment and goal setting offers an example to other regions and countries of how to increase the quality and efficiency of drug prescribing within limited resources.

Mesh:

Year:  2009        PMID: 19622268

Source DB:  PubMed          Journal:  Qual Prim Care        ISSN: 1479-1064


  18 in total

1.  Adherence to hospital drug formularies and cost of drugs in hospitals in Denmark.

Authors:  Hanne T Plet; Jesper Hallas; Lene J Kjeldsen
Journal:  Eur J Clin Pharmacol       Date:  2013-06-14       Impact factor: 2.953

2.  Compliance with quality prescribing indicators linked to financial incentives: what about not incentivized indicators?: an observational study.

Authors:  R Fernández Urrusuno; P Pérez Pérez; M C Montero Balosa; C Márquez Calzada; B Pascual de la Pisa
Journal:  Eur J Clin Pharmacol       Date:  2013-12-03       Impact factor: 2.953

3.  Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.

Authors:  Steven G Morgan; Winny Li; Brandon Yau; Nav Persaud
Journal:  CMAJ       Date:  2017-02-27       Impact factor: 8.262

4.  Forecasting drug utilization and expenditure in a metropolitan health region.

Authors:  Björn Wettermark; Marie E Persson; Nils Wilking; Mats Kalin; Seher Korkmaz; Paul Hjemdahl; Brian Godman; Max Petzold; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-05-17       Impact factor: 2.655

5.  How to best assess quality of drug treatment in patients with heart failure.

Authors:  Ramin Zarrinkoub; Thomas Kahan; Sven-Erik Johansson; Per Wändell; Märit Mejhert; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2016-04-11       Impact factor: 2.953

6.  Perceptions, Expectations, and Experience of Physicians About Pharmacists and Pharmaceutical Care Services in Pakistan: Findings and Implications.

Authors:  Khezar Hayat; Zia Ul Mustafa; Brain Godman; Muhammad Arshed; Jiaxing Zhang; Faiz Ullah Khan; Fahad Saleem; Krizzia Lambojon; Pengchao Li; Zhitong Feng; Yu Fang
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

7.  Policies to enhance prescribing efficiency in europe: findings and future implications.

Authors:  Brian Godman; William Shrank; Morten Andersen; Christian Berg; Iain Bishop; Thomas Burkhardt; Kristina Garuoliene; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Julie Lonsdale; Rickard E Malmström; Jaana E Martikainen; Vita Samaluk; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; Lesley Tilson; F Cankat Tulunay; Vera Vlahović-Palčevski; Kamila Wendykowska; Bjorn Wettermark; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2011-01-07       Impact factor: 5.810

Review 8.  Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors:  Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-05

9.  Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Authors:  Brian Godman; Anna Bucsics; Thomas Burkhardt; Jutta Piessnegger; Manuela Schmitzer; Corrado Barbui; Emanuel Raschi; Marion Bennie; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-01-07       Impact factor: 5.810

10.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.